Obuchowicz Rafał, Lasek Julia, Wodziński Marek, Piórkowski Adam, Strzelecki Michał, Nurzynska Karolina
Department of Diagnostic Imaging, Jagiellonian University Medical College, 30-663 Krakow, Poland.
Faculty of Geology, Geophysics and Environmental Protection, AGH University of Krakow, 30-059 Krakow, Poland.
Diagnostics (Basel). 2025 Jan 24;15(3):282. doi: 10.3390/diagnostics15030282.
Humanity stands at a pivotal moment of technological revolution, with artificial intelligence (AI) reshaping fields traditionally reliant on human cognitive abilities. This transition, driven by advancements in artificial neural networks, has transformed data processing and evaluation, creating opportunities for addressing complex and time-consuming tasks with AI solutions. Convolutional networks (CNNs) and the adoption of GPU technology have already revolutionized image recognition by enhancing computational efficiency and accuracy. In radiology, AI applications are particularly valuable for tasks involving pattern detection and classification; for example, AI tools have enhanced diagnostic accuracy and efficiency in detecting abnormalities across imaging modalities through automated feature extraction. Our analysis reveals that neuroimaging and chest imaging, as well as CT and MRI modalities, are the primary focus areas for AI products, reflecting their high clinical demand and complexity. AI tools are also used to target high-prevalence diseases, such as lung cancer, stroke, and breast cancer, underscoring AI's alignment with impactful diagnostic needs. The regulatory landscape is a critical factor in AI product development, with the majority of products certified under the Medical Device Directive (MDD) and Medical Device Regulation (MDR) in Class IIa or Class I categories, indicating compliance with moderate-risk standards. A rapid increase in AI product development from 2017 to 2020, peaking in 2020 and followed by recent stabilization and saturation, was identified. In this work, the authors review the advancements in AI-based imaging applications, underscoring AI's transformative potential for enhanced diagnostic support and focusing on the critical role of CNNs, regulatory challenges, and potential threats to human labor in the field of diagnostic imaging.
人类正处于技术革命的关键节点,人工智能(AI)正在重塑传统上依赖人类认知能力的领域。由人工神经网络的进步推动的这一转变,已经改变了数据处理和评估方式,为利用人工智能解决方案解决复杂且耗时的任务创造了机会。卷积网络(CNN)和GPU技术的应用通过提高计算效率和准确性,已经彻底改变了图像识别。在放射学中,人工智能应用对于涉及模式检测和分类的任务特别有价值;例如,人工智能工具通过自动特征提取提高了在各种成像模式下检测异常的诊断准确性和效率。我们的分析表明,神经成像和胸部成像,以及CT和MRI模式,是人工智能产品的主要关注领域,这反映了它们高临床需求和复杂性。人工智能工具还用于针对肺癌、中风和乳腺癌等高发性疾病,突出了人工智能与重大诊断需求的契合度。监管环境是人工智能产品开发的一个关键因素,大多数产品根据医疗器械指令(MDD)和医疗器械法规(MDR)在IIa类或I类中获得认证,表明符合中等风险标准。我们发现,2017年至2020年期间人工智能产品开发迅速增加,在2020年达到峰值,随后近期趋于稳定和饱和。在这项工作中,作者回顾了基于人工智能的成像应用的进展,强调了人工智能在增强诊断支持方面的变革潜力,并关注卷积神经网络的关键作用、监管挑战以及诊断成像领域对人类劳动的潜在威胁。